ESMO 2020 extra: In HER2+ metastatic breast cancer, tucatinib doesn't degrade QoL


  • Ben Gallarda
  • Univadis Clinical Summaries
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • QoL was no different between tucatinib and placebo in patients with HER2+ metastatic breast cancer in the HER2CLIMB trial.
  • Previous reports indicated that tucatinib prolonged PFS and OS.

Why this matters

  • Findings should be reassuring to patients.

Study design

  • Randomized controlled trial of tucatinib + trastuzumab + capecitabine compared with placebo + trastuzumab + capecitabine (n=330) over the course of treatment every 2 or 3 cycles.
  • QoL was measured by European Quality of Life - 5 Dimensions - 5 Levels (EQ-5D-5L) and visual analog scale (VAS) measuring pain.
    • 5 domains are mobility, self-care, usual activities, pain/discomfort, and anxiety/depression.
    • 5 levels were no, slight, moderate, severe, or extreme.
  • Funding: Seattle Genetics.

Key results

  • No differences between groups across all 5 dimensions of the EQ-5D-5L.
    • QoL and VAS were stable across the duration of treatment for both groups.
    • Decline in EQ-5D-5L was not observed for either group.

Limitations

  • Data were available for only half of the total patients (330 of 612 patients).